References
- Bullock LP, Gupta C, Bardin CW. A mechanism for the antiandrogenic action of medrogestone. Int J Androl 1978; 1: 32–42
- Chubb C, Ewing LL. Steroid secretion by in vitro perfused testis: Inhibitors of testosterone biosynthesis. Am J Physiol 1979; 237(3)E239–E246
- Deghenghi R, Revesz C, Gaudry RJ. New synthesis and structure activity relationship in the 17-alkylated progesterone series. J Med Chem 1963; 6: 301–304
- Givner ML, Dvornik D. Inhibition of testosterone biosynthesis by medrogestone. Experientia 1972; 28: 1105–1106
- Jagarinec N, Givner ML. Inhibition of testosterone metabolism by medrogestone in rat ventral prostate in vivo and in vitro. Arch Androl 1981; 7: 39–44
- Krebs AH, Henseleit K. Untersuchungen ueber die Harnstoffbildung im Tierkoerper. Z Physiol Chem 1932; 210: 33–66
- Larsson H, Stensson M. Effect of bis (p-Hydroxyphenyl)-cyclo-hexylidenemethane(F 6060) on the conversion of pregnenolone to δ43-ketosteroids in vitro. Acta Endocrinol 1967; 55: 673–684
- Nishina T, Sakai Y, Kimura M. A specific method for the Determination of δ4-3-ketoste-roids with p-nitrophenylhydrazine. Steroids 1964; 4: 255–266
- Paulson DF, Kane RD. Medrogestone: A prospective study in the pharmaceutical management of benign prostatic hyperplasia. J Urol 1975; 113: 811–815
- Rangno RE, McLeod PJ, Ruedy J, Ogilvie RI. Treatment of benign prostatic hypertrophy with medrogestone. Clin Pharmacol Ther 1971; 12: 658–665
- Revesz C, Chappel CI. Biological activity of medrogestone, a new orally active progestin. J Reprod Fertil 1966; 12: 473–487
- Sufrin G, Coffey DS. A new model for studying the effect of drugs on prostatic growth. Invest Urol 1973; 11: 45–54